MELK and non-small cell lung carcinoma: Similarly, an upregulated 22-GS, including mainly proliferation-related genes, was identified in biopsies of NSCLC patients lacking complete pathologic response to chemo-immunotherapy; among these, post-treatment upregulation of MELK, FOXM1, CDKN3, and CDK1 was coupled with low pre-treatment PD-L1 levels and high densities of follicular T helper cells and M2 macrophages post-treatment [52].